Two-Pronged attack on rare blood cancers shows promise
NCT ID NCT01787487
Summary
This study is testing whether combining two existing drugs, ruxolitinib and azacytidine, is a better treatment for people with myelofibrosis and related blood cancers. The trial enrolled 121 patients to see if this combination can improve their disease status more effectively than standard treatments. Researchers are measuring how well the treatment works and monitoring its safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.